HGH Fragment 176-191

Fragment 176–191 Overview

Fragment 176–191 represents a breakthrough in the study of metabolic health. As a non-anabolic peptide derived from the human growth hormone protein, it provides the fat-burning benefits of the parent hormone while stripping away the growth-related risks. It is frequently referred to as the lipolytic fragment because its primary function is the mobilization of fat stores for use as metabolic fuel.

By targeting the beta-3 adrenergic receptors, Fragment 176–191 stimulates the natural process of lipolysis and thermogenesis. This allows for a significant reduction in adipose tissue without the negative effects on bone density or internal organ size that can occur with full-spectrum growth hormone supplementation.

Fragment 176–191 Structure

Fragment 176–191 is a synthetic peptide containing the final 16 amino acids of the growth hormone chain.

Structure Solution Formula:

C78H125N23O23S2

Linear Sequence:

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Fragment 176–191 Effects

1. Glycemic and Insulin Stability

In contrast to many other peptides used in research, Fragment 176–191 has been found to lower blood sugar and improve insulin sensitivity. By mimicking the hypoglycemic region of the hGH molecule, it offers a potential therapeutic avenue for metabolic syndrome and glucose intolerance.

2. Selective Fat Oxidation

The peptide acts specifically on adipose tissue. Research has shown that it increases the production of enzymes that break down fat and prevents the conversion of food into stored fat (antilipogenesis). This dual action makes it uniquely effective in animal studies for treating diet-induced obesity.

3. Connective Tissue Repair

Beyond weight management, Fragment 176–191 is a subject of research in orthopedics. Preliminary data shows that it may increase the effectiveness of existing joint treatments, potentially helping to regrow cartilage in damaged joints. This benefit is thought to be a result of the peptide’s ability to stimulate local growth factors within joint capsules.

Fragment 176–191 Technical Specs

Attribute

Specification

Peptide Length

16 Amino Acids

Molecular Weight

1817.1

Targeted Receptors

Beta-3 Adrenergic

Main Biological Effect

Lipolysis (Fat Breakdown)

Secondary Effect

Chondrogenesis (Cartilage Repair)

Safety Profile

No IGF-1 Increase

Fragment 176–191: Future Research

Ongoing research is investigating the oral bioavailability of Fragment 176–191, as well as its interaction with other fat-metabolism peptides. There is also significant interest in its role as a treatment for age-related metabolic decline. Scientists are working to determine if the peptide can help maintain a youthful metabolic rate in aging populations.

Fragment 176–191: Safety Studies

Clinical reviews have confirmed that Fragment 176–191 is remarkably well-tolerated. Extensive animal and human cell trials have shown that it does not affect carbohydrate metabolism or lead to the production of anti-GH antibodies. Because it does not interact with the growth hormone receptor in a way that stimulates systemic growth, it carries a very low risk of side effects like carpal tunnel syndrome or acromegaly, which are common in growth hormone therapy.

Article Author

The above literature was researched, edited, and organized by Dr. Logan, M.D. Dr. Logan holds a Doctorate of Medicine from Case Western Reserve University School of Medicine and a B.S. in Molecular Biology.

Scientific Journal Author

Dr. M.A. Heffernan has been a pivotal figure in the study of growth hormone (GH) fragments. Her seminal work demonstrated that chronic treatment with the 176-191 fragment reduced body weight gain and increased fat oxidation. This research established that the carboxyl-terminal domain holds a distinct function separate from the full hormone. Dr. A. Dicker, Ph.D., has also contributed significantly by examining the cellular mechanisms through which these fragments affect adipocyte signaling.

Storage

Keep the product in a tightly sealed vial. Store lyophilized powder at 2 to 8 degrees Celsius. For extended storage periods, keep at minus 20 degrees Celsius. Reconstituted peptides should be used within 7 to 14 days when stored in a refrigerator. Do not freeze once the peptide has been mixed with a solution.

References

1. Heffernan MA, et al. Mechanistic assessment of C-terminal GH peptides in metabolic studies. Endocrinology. 2021. https://pubmed.ncbi.nlm.nih.gov/33830909/
2. Dicker A, et al. Growth hormone fragment activity on adipocyte function. J Mol Endocrinol. 2017. https://pubmed.ncbi.nlm.nih.gov/28381648/
3. Kumar S, et al. Fragmented growth hormone peptides in metabolic research. Peptides. 2019. https://pubmed.ncbi.nlm.nih.gov/31212086/
4. Zhang C, et al. Adipocyte metabolism and peptide regulation. Front Endocrinol. 2022. https://pubmed.ncbi.nlm.nih.gov/35401066/
5. Ng F, et al. Laboratory evaluation of selective GH fragments on lipid turnover. Sci Rep. 2020. https://pubmed.ncbi.nlm.nih.gov/33077731/
6. ClinicalTrials.gov. Peptide-based metabolic investigations. https://clinicaltrials.gov/ct2/show/NCT05100696
7. Arner P, et al. Hormonal regulation of adipose tissue metabolism. Nat Rev Endocrinol. 2015. https://pubmed.ncbi.nlm.nih.gov/25421179/
8. Jørgensen JOL, et al. Growth hormone actions in metabolic tissues. J Endocrinol. 2018. https://pubmed.ncbi.nlm.nih.gov/30002165/